Journals / The Anatolian Journal of Cardiology / 2017 / Cilt: 17 - Sayı: 5

The effect of high-dose steroid treatment used for the treatment of acute demyelinating diseases on endothelial and cardiac functions

Pages
392–397
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies are needed to evaluate the development of cardiovascular mortality and morbidity in patients receiving this type of treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The cardiovascular effects of short-term high-dose steroid treatment (pulse steroid treatment) have not yet been clarified.
📊
Key Findings & Data:We examined the short- and long-term effects of pulse steroid treatment in demyelinating diseases on endothelial and cardiac functions.Methods: In this prospective study, we included 35 patients (20 females and 15 males; mean age, 32.8±9.3 years) who were not treated with steroids and who were previously diagnosed with multiple sclerosis or neuromyelitis optica.
💡
Conclusion & Impact:Future studies are needed to evaluate the development of cardiovascular mortality and morbidity in patients receiving this type of treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The cardiovascular effects of short-term high-dose steroid treatment (pulse steroid treatment) have not yet been clarified. We examined the short- and long-term effects of pulse steroid treatment in demyelinating diseases on endothelial and cardiac functions.Methods: In this prospective study, we included 35 patients (20 females and 15 males; mean age, 32.8±9.3 years) who were not treated with steroids and who were previously diagnosed with multiple sclerosis or neuromyelitis optica. Patients were evaluated before, 1 week after, and 3 months after the steroid treatment. Brachial artery flow-mediated relaxation and cardiac systolic/diastolic function were evaluated using echocardiography to assess physical examination results, carotid intima-media thickness, and endothelial function.Results: There was no difference between biochemical values, systolic function, left ventricular dimensions, and carotid intima-media thicknesses in the three evaluation periods. There were significant increases in the body mass index, body weight, and systolic/diastolic blood pressure measurements at 1 week and 3 months after treatment (p<0.001). There was a significant decrease in brachial artery flow-mediated relaxation at 1 week and 3 months (1 versus 2, p=0.042; 1 versus 3, p=0.003). In Doppler measurements at 1 week and 3 months, there was an increase in mitral A velocity, IVRT, and EDT values and a decrease in the E/A ratio in line with diastolic dysfunction.Conclusion: Pulse steroid therapy used for demyelinating diseases deteriorated endothelial and left ventricular diastolic functions in the early and late periods. Future studies are needed to evaluate the development of cardiovascular mortality and morbidity in patients receiving this type of treatment.

🔖

Cite This Article

ÇALDIR, M. V., ÇELİK, G. K., ÇİFTCİ, Ö., MÜDERRİSOĞLU, İ. H. (2017). The effect of high-dose steroid treatment used for the treatment of acute demyelinating diseases on endothelial and cardiac functions. The Anatolian Journal of Cardiology, Cilt: 17 - Sayı: 5, 392–397. https://ajindex.com/articles/365352

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006; 332: 525-7.
  2. Shaygannejad V, Ashtari F, Alinaghian M, Norouzi R, Salari M, Fate- hi F. Short-term safety of pulse steroid therapy in multiple sclerosis relapses. Clin Neuropharmacol 2013; 36: 1-3. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 2005; 139: 1101-8.
  3. Funauchi M, Ikoma S, Imada A, Kanamaru A. Combination of im- munoadsorption therapy and high-dose methylprednisolone in patients with lupus nephritis; possible indications in patients with early stage. J Clin Lab Immunol 1997; 49: 47-57. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996; 132: 1435-9.
  4. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 2002; 46: 2553-63.
  5. Tyblova M, Kalincik T, Zikan V, Havrdova E. Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. Eur J Neurol 2015; 22: 624-32.
  6. Zimmerman J, Fainaru M, Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism 1984; 33: 521-6.
  7. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sym- pathoadrenal system. N Engl J Med 1996; 334: 374-81. Raynauld JP. Cardiovascular mortality in rheumatoid arthritis: how harmful are corticosteroids? J Rheumatol 1997; 24: 415-6. del Rincón I, O'Leary DH, Haas RW, Escalante A. Effect of glucocor- ticoids on the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3813-22.
  8. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013; 9: 30. Vasheghani-Farahani A, Sahraian MA, Darabi L, Aghsaie A, Minagar A.Incidence of various cardiac arrhythmias and conduc- tion disturbances due to high dose intravenous methylpredniso- lone in patients with multiple sclerosis. Neurol Sci 2011; 309: 75-8.
  9. Faggiano A, Pivonello R, Spiezia S, De Martino MC, Filippella M, Di Somma C, et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease dur- ing active disease and 1 year after disease remission. J Clin Endo- crinol Metab 2003; 88: 2527-33.
  10. Brotman DJ, Girod JP, Garcia MJ, Patel JV, Gupta M, Posch A, et al. Eff